Abstract Body

Background

Prior SARS-CoV-2 infection and vaccination impact the magnitude and durability of anti-receptor binding domain (RBD) IgG. We aimed to characterise longitudinal anti-RBD dynamics in HCWs with and without prior infection in the SORTED (Seroprevalence, Seroconversion Rates and Transmission Dynamics of SARS-CoV-2 among Healthcare Workers) study.

Methods

Recruitment occurred from July 2020 to September 2021 with subjects grouped into prior SARS-CoV-2 infection (group 1) and naïve (group 2) . Participants underwent SARS-CoV2 mRNA vaccination during follow up, with participants receiving  2 doses by week 12 and a booster by week 48. Serum samples were collected at weeks 0, 12, and 48 weeks and tested for anti-RBD IgG titres using an in-house quantitative electrochemiluminescence assay. A threshold anti-RBD titre of 456 BAU/ml was considered a correlate of protection. Longitudinal changes in log transformed titres were modelled as left-censored data using a Bayesian piecewise linear mixed-effects model. Associations with change were evaluated using interaction between time spline terms and explanatory variables. Posterior slopes were exponentiated to reflect percentage-changes per week and reported with credible Intervals (CrI). 

Results

were recruited (group 1, n=106; group 2 n= 143). Mean log anti-RBD IgG over time and percent change % week within and between groups are presented in figure 1. Group 1 had 5.23-fold higher baseline anti-RBD titres compared to group 2 (95% CrI 4.50–6.0%); 194(77.9%) achieved a threshold anti-RBD while 129(51.8%) remained above the threshold for 2 or 3 visits. In group 2, titres rose steeply before week 12 (+44% per week, 95% CrI 36–53%) but slowed after (+5% per week, 95% CrI 4–7). Group 1 showed smaller early increases (+30% per week, 95% CI 25–35%) and declined thereafter (–2% per week, 95% CrI –3 to –1%). Slopes were significantly attenuated in group 1, both before (–10% per week, 95% CI –16 to –4) and after week 12 (–7% per week, 95% CrI –9 to –5). Receipt of vaccine by week 12 boosted titres by 172% (95% CrI 92–292), while a further dose by week 48 yielded a smaller 26% rise (95% CrI –44 to 186). No associations were observed between antibody dynamics and age, sex, or ethnicity. 

Conclusions

Both groups mounted strong anti-RBD responses, though titres rose more slowly and plateaued in HCWs with prior infection compared to modest increases beyond week 12 in naïve HCW. Further research is required to evaluate anti-RBD durability and functional immunity. 

Table or Figure